Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer

Current Opinion in Urology

Volumn 19, Issue 3, 2009, Pages 221-226

  Botchorishvili, George ^a,b   Matikainen, Mika P ^a,c   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b A Tsulukidze National Centre of Urology   (Georgia)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Diagnosis; Mortality reduction; Prostate cancer; Prostate specific antigen; Risk stratification

Indexed keywords

FINASTERIDE; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN SPECIFICITY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; HUMAN; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; MALE; PREDICTION AND FORECASTING; PROSTATE TUMOR; RISK FACTOR;

HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 67649713143     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832a2d10     Document Type: Review

References (91)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Cancer J Clin 2006; 56:106-130.
2. Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. Can J Urol 2008; 15:4363-4374. An analytical article on PSA and other kallikreins in detection and prognostication of PCa.
3. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8:268-278. This article deals with basic issues on PSA biology and PSA in detection, screening, and prognostication.
4. Catalona WJ, Loeb S, Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006; 144:441-443. (Pubitemid 46768167)
5. National Cancer Institute Division of Cancer Control and Population Sciences. Surveillance, epidemiology, and end results (SEER) [Internet]. 2007 [cited 2007 July 28]; available from: http://www.seer.cancer.gov/resources/.
6. National Center for Health Statistics. Monitoring the Nation's Health [Internet]. 2007 [cited 2007 July 28]; available from www.cdc.gov/nchs.
7. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett 2007; 249:30-39.
8. Hugosson J, Aus G, Lilja H, et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100:1397-1405. (Pubitemid 38366842)
9. Maattanen L, Hakama M, Tammela TL, et al. Specificity of serum prostatespecific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 2007; 96:56-60. (Pubitemid 46094639)
10. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224. (Pubitemid 36859473)
11. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
12. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostatespecific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294:66-70. (Pubitemid 41002840)
13. Vickers AJ, Lilja H. Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem 2009; 55:15-17. An important discussion on cut-points of laboratory values.
14. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008; 6:19. An important article showing diagnostic value of kallikrein markers.
15. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008; 6:6.
16. Steuber T, Niemela P, Haese A, et al. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005; 63:13-18. (Pubitemid 40365386)
17. Steuber T, Vickers AJ, Haese A, et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006; 118:1234-1240. (Pubitemid 43185611)
18. Steuber T, Vickers AJ, Serio AM, et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007; 53:233-240. This article shows predictive value of kallikrein panel. (Pubitemid 46338267)
19. Jansen FH, Roobol M, Jenster G, et al. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 2008. [Epub ahead of print]
20. Raaijmakers R, de Vries SH, Blijenberg BG, et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screendetected men within the PSA range 4-10 ng/ml. Eur Urol 2007; 52:1358-1364. (Pubitemid 47445980)
21. Wenske S, Korets R, Cronin AM, et al. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer 2009; 124:659-663.
22. Vickers AJ, Ulmert D, Serio AM, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologicallybased screening strategy. Int J Cancer 2007; 121:2212-2217. (Pubitemid 47585600)
23. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25:431-436. This article on the large cohort from Malmö demonstrated that PSA and other kallikreins, after single measurement, could predict development of PCa 25 years before its clinical manifestation. (Pubitemid 350002992)
24. Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006; 52:235-239. (Pubitemid 43185484)
25. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26:835-841.
26. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298:2275-2280. (Pubitemid 350146217)
27. Loeb S, Chan DW, Sokoll L, et al. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol 2008; 180:1959- 1962; discussion 1962-1963
28. Jansen FH, Roobol M, Bangma CH, et al. Clinical impact of new prostatespecific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008; 54:1999-2006. The above article shows important data showing value of assay standardization. (Pubitemid 352774033)
29. Sotelo RJ, Mora KE, Perez LH, et al. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. Urology 2007; 69:1143-1146.
30. Vignati G, Giovanelli L. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA. Int J Biol Markers 2007; 22:295-301. (Pubitemid 351256266)
31. Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol 2008; 129:952-958.
32. Stephan C, Kahrs AM, Klotzek S, et al. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med 2008; 46:623-629. (Pubitemid 351749111)
33. Stenman UH, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344:1594-1598. (Pubitemid 24365358)
34. Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007; 120:1499-1504. (Pubitemid 46355384)
35. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289:2695-2700. (Pubitemid 37430140)
36. Dotan ZA, Bianco FJ Jr, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005; 23:1962- 1968.
37. Oudard S, Banu E, Scotte F, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007; 18:1828-1833. (Pubitemid 350111569)
38. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25:2035-2041. (Pubitemid 46972788)
39. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521-1527. (Pubitemid 44680903)
40. Eggener SE, Roehl KA, Catalona WJ. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol 2005; 174:500-504. (Pubitemid 40981584)
41. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174:2191-2196. (Pubitemid 41611772)
42. Khatami A, Aus G, Damber JE, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European Randomized Study of Screening for Prostate Cancer, Sweden section. Int J Cancer 2007; 120:170-174.
43. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125-135.
44. Loeb S, Kettermann A, Carter HB, et al. Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol 2008; 180:1314-1317; discussion 1317.
45. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179:2181-2185; discussion 2185-2186
46. Hamilton RJ, Aronson WJ, Terris MK, et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179:1785-1789; discussion 1789-1790
47. Teeter AE, Banez LL, Presti JC Jr, et al. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol 2008; 180:1980-1984; discussion 1985.
48. O'Brien MF, Fearn PA, Smith B, et al. Which definition of PSA doubling time or velocity best predicts outcome after radical prostatectomy? [Abstract]. Presented at the Am Urol Assoc Annual Meeting, Anaheim, California; 19-24 May 2007.
49. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27:398-403. An important systematic review to analyze predictive value of PSA kinetics.
50. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
51. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58:411-416. (Pubitemid 32816360)
52. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67:316-320. (Pubitemid 43189848)
53. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Nonnotified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984; 23:305-313.
54. Tornblom M, Eriksson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004; 108:122-129.
55. Aus G, Damber JE, Khatami A, et al. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005; 165:1857-1861.
56. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53:68-80.
57. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007; 99:1881-1887. (Pubitemid 351767195)
58. Laurila M, Tammela TL, Auvinen A, et al. Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer 2009; 124:547-552.
59. Schroder FH. Screening for prostate cancer (PC): an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 2008; 26:533-541.
60. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009. [Epub ahead of print]
61. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58:417-424. (Pubitemid 32816361)
62. Okihara K, Nakanishi H, Nakamura T, et al. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol 2005; 12:662-667. (Pubitemid 41725492)
63. Song C, Ahn H, Lee MS, et al. Mass screening for prostate cancer in Korea: a population based study. J Urol 2008; 180:1949-1952; discussion 1952-1953
64. Bergstralh EJ, Roberts RO, Farmer SA, et al. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology 2007; 70:936-941. (Pubitemid 350192584)
65. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 2006; 166:38-43. (Pubitemid 43063839)
66. Gohagan JK, Prorok PC, Hayes RB, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21 (6 Suppl):251S-272S.
67. Hoffman RM. Viewpoint: limiting prostate cancer screening. Ann Intern Med 2006; 144:438-440. (Pubitemid 46768166)
68. Ilic D, O'Connor D, Green S, et al. Screening for prostate cancer. Cochrane Database Syst Rev 2006:CD004720.
69. Nguyen PL, Chen MH, Catalona WJ, et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: implications for management. Cancer 2008; 113:3146-3152.
70. Grubb RL 3rd, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008; 102:1524-1530.
71. Barry MJ. Screening for prostate cancer among men 75 years of age or older. N Engl J Med 2008; 359:2515-2516.
72. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270:948-954.
73. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23:8165-8169.
74. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180:150-154; discussion 154.
75. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99:526-532. (Pubitemid 47073555)
76. Sokoll LJ,Wang Y, Feng Z, et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008; 180:539-543; discussion 543.
77. Shariat SF, Canto EI, Kattan MW, et al. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004; 6:58-72.
78. Diamandis EP. POINT: EPCA-2 - a promising new serum biomarker for prostatic carcinoma? Clin Biochem 2007; 40:1437-1439. This article deals with the importance of validation of the new biomarkers and the quality of the scientific literature.
79. Muller H, Haug U, Rothenbacher D, et al. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. J Urol 2008; 180:1309-1312; discussion 1312-1313
80. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179:1587-1592.
81. Fritzsche FR, Jung M, Tolle A, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008; 54:1097-1106.
82. Gupta A, Lotan Y, Ashfaq R, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2008. [Epub ahead of print]
83. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54:1081-1088.
84. Helfand BT, Loeb S, Cashy J, et al. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol 2008; 179:2197-2201; discussion 2202.
85. Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67:762-768.
86. Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69:714-720. (Pubitemid 46574950)
87. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179:1804-1809; discussion 1809-1810
88. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-284. (Pubitemid 43121812)
89. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224-1235.
90. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180:1975-1978; discussion 1978-1979
91. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescencebased PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13:939-943. (Pubitemid 46340370)